In 2023, peptic ulcer and GORD medicine sales in Canada were valued at 696 million USD PPP. From 2024 to 2028, the market is expected to see a gradual decline. The year-on-year variation indicates a decrease of 1.31% from 2024 to 2025, 1.12% from 2025 to 2026, 0.97% from 2026 to 2027, and 0.83% from 2027 to 2028. The compound annual growth rate (CAGR) from 2024 to 2028 is projected to be a negative 1.06%.

Future trends to watch for:

Potential shifts in treatment protocols for peptic ulcer and GORD that could alter medicine demand.
Emerging advancements in pharmaceuticals or alternative therapies potentially impacting market dynamics.
Regulatory changes and healthcare budget constraints influencing medicine sales trends.